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Abstract: Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and 
mortality worldwide. Indications for the use of long-acting β2-agonists (LABAs) and inhaled 
corticosteroids (ICS) in patients with COPD are described in the various international guidelines, 
but no special recommendations are made concerning the use of combination inhalers containing 
a LABA as well as an ICS. To determine the place of combination inhalers in the treatment of 
COPD we reviewed recent literature concerning this subject. On molecular level ICS/LABA 
combination therapy has anti-inﬂ  ammatory properties which cannot be attributed to ICS alone. 
All clinical studies indicate that the two available combinations (salmeterol/ﬂ  uticasone and 
formoterol/budesonide) signiﬁ  cantly reduce exacerbation rate of moderate/severe exacerbations 
when compared with placebo. Some studies also showed a signiﬁ  cant reduction in exacerbation 
rate compared with LABA monotherapy, but not compared with ICS monotherapy. From the 
patient’s perspective, ICS/LABA combination inhalers are the ﬁ  rst choice when both need to 
be prescribed, possibly improving patient compliance for ICS. Currently little evidence is avail-
able to predict if ﬂ  exible treatment with LABA/ICS combination inhalers will improve disease 
control in COPD. Further studies are needed to elucidate the clinical beneﬁ  t of combination 
inhalers versus the individual components in different inhalers, and to investigate the clinical 
beneﬁ  t of ﬂ  exible dosing of combination inhalers in patients with COPD.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity 
and mortality worldwide, and results in an economic and social burden that is both 
substantial and increasing (GOLD 2006). Tobacco smoking is the main risk factor 
for COPD, although other inhaled noxious particles and gases may contribute to the 
development of COPD. The treatment of stable COPD consists primarily of smoking 
cessation, pharmacological intervention with bronchodilators and corticosteroids, long-
term oxygen treatment, and pulmonary rehabilitation. Three types of bronchodilator 
are in common clinical use: β2-agonists, anticholinergic drugs (both short and long 
acting), and methylxanthines. 
Indications for the use of long-acting β2-agonists (LABAs) and inhaled corticoste-
roids (ICS) in patients with COPD are described in the various international guidelines. 
However, as the deﬁ  nition and classiﬁ  cation of COPD differs in four major guidelines, 
ie, the Global Initiative for Chronic Obstructive Lung Disease (GOLD), British Tho-
racic Society (BTS), the British National Institute for Clinical Excellence (NICE), and 
American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines 
(BTS 1997; Celli and MacNee 2004; NICE 2004; GOLD 2006), the recommendations 
for treatment with LABAs and ICS also differ. The GOLD guidelines (GOLD 2006) 
recommend prescribing a LABA starting at stage II (forced expiratory volume in 1 s International Journal of COPD 2007:2(2)  108
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[FEV1] 50% but <80%) whereas the ATS/ERS taskforce 
(Celli and MacNee 2004) recommend starting with a LABA 
when symptoms persist whilst using as-needed short-acting 
bronchodilators. Since the BTS guidelines date from 1997 
(BTS 1997), they state that at that time only limited evidence 
for the efﬁ  cacy of LABAs in COPD was available. At the 
time the BTS guidelines were formulated, the use of a LABA 
was only recommended in patients who demonstrated a 
bronchodilatory response to β2-agonists, with efﬁ  cacy being 
monitored by assessment of symptoms and FEV1. 
The NICE guidelines (NICE 2004), developed with the 
involvement of members of the BTS, state LABAs should be 
used in patients who remain symptomatic despite treatment 
with short-acting bronchodilators and in patients with two 
or more exacerbations per year.
All guidelines acknowledge that regular treatment with 
ICS is appropriate for patients with symptomatic COPD and 
an FEV1 <50% who experience repeated exacerbations.
In all four guidelines no special recommendations are 
made concerning the use of combination inhalers containing 
a LABA as well as an ICS except to suggest their use if both 
drugs are being prescribed concomitantly. 
Since combination inhalers containing ICS and LABAs 
have become commonly available for the treatment of patients 
with pulmonary disorders, more data concerning their use 
in patients with COPD now exists. This paper discusses 
the possible advantages of using LABA/ICS combination 
inhalers over using the separate components; the clinical 
importance of differences between the two available inhalers: 
salmeterol/ﬂ  uticasone and budesonide/formoterol; safety and 
tolerability; and the possibilities of ﬂ  exible dosing. 
Efﬁ  cacy of combination treatment 
in COPD
In order to assess the additive effect of combination treatment 
in patients with COPD, it is imperative to consider the effect 
of treatment at different levels: molecular level, population 
level, and individual level.
Molecular level
There is evidence that not only do ICS target the inﬂ  am-
matory process and LABAs cause bronchodilation, but 
also that there is considerable interaction between the two 
components. Corticosteroids have been shown to increase β2-
receptor mRNA and reverse receptor downregulation caused 
by prolonged exposure to β2-agonists (Brodde et al 1988; Mak 
et al 1995a, 1995b). In addition, there is persuasive evidence 
that in asthma, β2-agonists also target certain aspects of the 
inﬂ  ammatory process (Wallin et al 1999; Jeffery et al 2002). 
In patients with COPD, Haque and colleagues (2006) recently 
showed that the addition of salmeterol 50 μg to ﬂ  uticasone 
100 μg resulted in an enhancement of glucocorticoid receptor 
nuclear translocation in macrophages that was equivalent to 
increasing the ﬂ  uticasone dose ﬁ  vefold. 
A recent study by Barnes and colleagues (2006) in patients 
with COPD showed a broad spectrum of anti-inﬂ  ammatory 
effects after 13 weeks’ treatment with salmeterol and ﬂ  uti-
casone that were not seen with placebo. A reduction in 
lung tissue obtained through endobronchial biopsies CD8+, 
CD45+, and CD4+ cell counts, sputum differential neutro-
phils, and total eosinophils and cells expressing genes for 
tumor necrosis factor-α and interferon-γ was seen in both 
current and former smokers with COPD (Table 1). A similar 
study in which ﬂ  uticasone propionate at the same dose and 
for the same duration was used alone to treat patients reported 
no effects on the number of biopsy subepithelial CD8+ or 
CD4+ cells in lung tissue (Gizycki et al 2002; Hattotuwa 
et al 2002). In other research (Gosman et al 2006), 6 months’ 
treatment with ﬂ  uticasone (500 μg twice daily [bid]) in 
patients with COPD reduced bronchial CD4 cell counts, 
whereas ﬂ  uticasone and salmeterol treatment (500/50 μg 
bid) showed additional reductions in CD8 cells. In a similar 
study, Yamauchi and colleagues (2006) observed a signiﬁ  -
cant reduction in the number of CD8 and MBP+ cells and 
a modest reduction in CD68 cells after 3 months’ treatment 
with salmeterol/ﬂ  uticasone. Treatment with ﬂ  uticasone alone 
did cause a reduction in MBP+ cells but failed to do so for 
CD8 and CD68 cells. These results imply that ICS/LABA 
combination therapy in COPD has anti-inﬂ  ammatory proper-
ties which cannot be attributed to ICS alone.
Population level
It is still unclear whether the pharmacological interaction 
observed between LABAs and ICS has an additive effect 
or a synergistic effect on clinical parameters in COPD. 
A pharmacological interaction has been suggested in 
asthma (Zetterstrom et al 2001), but no research has been 
performed in COPD comparing the effect of a LABA and 
ICS in separate inhalers versus a combination inhaler. 
A meta-analysis (Nelson et al 2003) of the effects of 
co-deposition of ﬂ  uticasone and salmeterol in patients with 
asthma showed a signiﬁ  cant increase in peak expiratory ﬂ  ow 
(PEF) compared with separate inhaler treatment. Although 
some questions were raised about the clinical importance 
of the size of the improvement (Lipworth and Fardon 2004; 
Metcalfe and Moodie 2004), the concept of a synergistic International Journal of COPD 2007:2(2)  109
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Table 1 Effects of salmeterol/ﬂ  uticasone and ﬂ  uticasone propionate on inﬂ  ammatory cell outcomes (fully published papers only)
Reference Medication  Duration  Inﬂ  ammatory cell outcomes
Barnes et al 2006  Salmeterol/ﬂ  uticasone   13 weeks  • SF signiﬁ  cantly reduced the absolute numbers of
 (SF)  50/500  μg (n = 55)      biopsy (CD45+) leukocytes, CD8+ cells, and CD4+ cells. 
 versus   • In biopsy SF signiﬁ  cantly decreases cells expressing 
       genes  for  TNF-α and IFN-γ.
  placebo (n = 69)   •  No signiﬁ  cant CD8:CD4 ratio differences or number of
       CD68+  cells.
Gizycki et al 2002  Fluticasone Propionate  3 month  • Compared with baseline, FP treatment had no signiﬁ  cant
 (FP)  500  μg bid (n = 14)      effects on the total number of inﬂ  ammatory cells, 
        lymphomononuclear cells, or macrophages in the 
       airway  mucosa.
 versus   • Compared with baseline and placebo FP did show a
       signiﬁ  cant reduction in the number of mucosal mast cells.
  placebo (n = 10)    • Compared with placebo the FP group had signiﬁ  cantly
        more neutrophils after treatment.
Hattotuwa et al 2002  Fluticasone propionate  3 month  • No signiﬁ  cant change in CD3+, CD8+, CD45, 
 (FP)  500  μg bid (n = 16)      CD45Ro+ cells, neutrophils, macrophages, mast cells and  
        eosinophils between baseline and end treatment.
  versus   • No signiﬁ  cant reduction in neutrophils compared
        with placebo treatment. In comparison with
        placebo mast cells showed a 25% decrease in 
        number in the subepithelium after FP (p = 0.04). 
  placebo (n = 14)   •  Signiﬁ  cant reduction in the numbers of mucosal   
       mast  cells.
     •  A reduction in the CD8:CD4 ratio in the 
        epithelium and the numbers of subepithelial mast
        cells in the FP group.
     •  CD4+ cells were signiﬁ  cantly raised in the placebo
        group in both epithelium and subepithelium
Abbreviations: FP, ﬂ  uticasone propionate; PF, ; SF, salmeterol/ﬂ  uticasone.
effect in a clinical setting remains intriguing. Further research 
in COPD comparing ICS/LABA combination therapy via a 
single inhaler versus separate inhalers will help to elucidate 
this issue further. 
In the mean time, many studies (Mahler et al 2002; 
Calverley et al 2003a, 2003b; Dal Negro et al 2003; Hanania 
et al 2003; Szafranski et al 2003; Wouters et al 2005) have 
been performed in COPD using both the salmeterol/ﬂ  utica-
sone and budesonide/formoterol combinations to examine 
the clinical efﬁ  cacy of a combination inhaler compared with 
placebo and the individual components. Besides changes in 
FEV1, most studies included parameters such as symptom 
scores, quality of life scores, and exacerbation frequency. 
Exacerbations not only inﬂ  uence quality of life in patients 
with COPD (Seemungal et al 1998), but also have an inde-
pendent negative impact on patient prognosis (Soler-Cataluna 
et al 2005). Acute severe exacerbations in COPD increase 
mortality, particularly if these exacerbations require hospital 
admission. Historical cohort studies (Mapel et al 2006a) and 
retrospective studies (Soriano et al 2003) suggest a positive 
effect on mortality for combined treatment with LABA and 
ICS. A recent study by Mapel and colleagues (2006b) showed 
the use of combination salmeterol/ﬂ  uticasone or concurrent 
ICS and LABA was consistently associated with signiﬁ  cantly 
improved survival in patients with COPD compared with 
those using short acting β2-agonists alone. With this in mind, 
the data from the TORCH (TOwards a Revolution in COPD 
Health) study group (Vestbo 2004) will be of particular inter-
est. The TORCH survival study is a placebo-controlled trial 
investigating all-cause mortality as the primary endpoint 
in over 6000 patients randomized to receive salmeterol/
ﬂ  uticasone propionate (50/500 μg bid), salmeterol (50 μg 
bid), ﬂ  uticasone propionate (500 μg bid), or placebo for 
3 years. Secondary endpoints include COPD exacerbation International Journal of COPD 2007:2(2)  110
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rate and health status measured by the St George’s Respira-
tory Questionnaire. Preliminary results show (GSK 2006) a 
17% relative reduction in mortality, and a 25% reduction in 
exacerbations, for patients receiving salmeterol/ﬂ  uticasone 
as compared with patients on placebo.
Combination therapy with salmeterol/
ﬂ  uticasone
Mahler and colleagues (2002) and Hanania and colleagues 
(2003) showed in studies of patients with COPD (Table 2) that 
24 weeks’ treatment with salmeterol/ﬂ  uticasone (50/500 
μg bid in the Mahler study and 25/500 μg bid for Hanania) 
signiﬁ  cantly increased PEF compared with the individual 
components and placebo. Interestingly, the Mahler study 
mentioned that the mean overall change from baseline 
in morning PEF with salmeterol/ﬂ  uticasone treatment 
(31.9 L/min) was greater than the sum of the mean changes 
from baseline observed with the individual components 
(12.9 and 16.8 L/min for ﬂ  uticasone and salmeterol, 
respectively). However, it is important to note that the 
actual difference in PEF was very small, and that the value 
of PEF measurements in COPD is limited. The TRISTAN 
(TRial of Inhaled STeroids ANd long-acting β2 agonists) 
(Calverley et al 2003a) study (Table 2) demonstrated that 
after 12 months’ treatment, the group receiving salme-
terol/ﬂ  uticasone (50/500 μg bid) had both pretreatment 
and post-treatment FEV1s that were signiﬁ  cantly greater 
than observed in the other treatment groups (salmeterol 
monotherapy, fluticasone monotherapy, or placebo), 
indicating that salmeterol/ﬂ  uticasone combination inhalers 
signiﬁ  cantly improve FEV1 and PEF versus the individual 
components. After post hoc analyses Calverley and col-
leagues (2006) concluded that, in the subgroup with a 
baseline FEV1 <50%, the improvement in lung function 
for the salmeterol/ﬂ  uticasone group was twice the sum 
of the individual components. This suggests a synergistic 
effect of salmeterol and ﬂ  uticasone in patients with more 
severe disease, but only additive effect in patients with 
mild disease (Singh 2006). Since ﬂ  uticasone had no sig-
niﬁ  cant effect in patients with the most severe disease, it 
could be argued that salmeterol “unlocks” corticosteroid 
insensitivity in these patients leading to a true synergistic 
effect.
Both the Mahler and the Hanania studies showed a 
signiﬁ  cant decrease in rescue medication use in the combina-
tion therapy group compared with the placebo and ﬂ  uticasone 
groups; the TRISTAN study also demonstrated a signiﬁ  cant 
decrease compared with the salmeterol group.
Neither the pooled data from the Mahler and Hanania 
studies, which were reported in a Cochrane review (Nannini 
et al 2004), nor the data from the TRISTAN group showed 
a signiﬁ  cant difference in the odds of experiencing an ex-
acerbation or the exacerbation rate when comparing salme-
terol/ﬂ  uticasone treatment against ﬂ  uticasone or salmeterol 
treatment. The post hoc analyses of the TRISTAN data 
(Calverley et al 2006) showed a higher proportion of patients 
experienced an exacerbation (60%) in the severe population 
(FEV1 <50% predicted) as compared with those in the FEV1 
50% predicted subgroup (44%). With all treatments, re-
ductions in exacerbations rates compared with placebo were 
statistically signiﬁ  cant in subjects with more severe COPD 
(FEV1 <50% predicted), but not signiﬁ  cant in those with 
FEV1 50% predicted.
Although designed differently to the trials mentioned 
above, the COSMIC (COPD and Seretide: Multi-Center 
Intervention and Characterization) study revealed similar 
results (Wouters et al 2005). After a 3-month run-in period 
with salmeterol/ﬂ  uticasone, patients were randomized to 
receive either salmeterol/ﬂ  uticasone or salmeterol alone. 
After 1 year’s treatment, the salmeterol/ﬂ  uticasone group 
experienced a signiﬁ  cantly smaller decline in FEV1 and PEF 
compared with the salmeterol group, but again no signiﬁ  cant 
difference was found in exacerbation rate.
A signiﬁ  cant difference in the mean number of exacer-
bations per year was found in a pilot study by Dal Negro 
and colleagues (2003). In this study patients with moder-
ate COPD, who were already treated with theophylline, 
received additional treatment with salmeterol/ﬂ  uticasone 
(50/250 μg bid), salmeterol (50 μg) alone or placebo. The 
combination treatment resulted not only in greater improve-
ments of respiratory function (such as FEV1 and morning 
PEF) and symptom scores compared with salmeterol alone 
or placebo, but also signiﬁ  cantly reduced the mean number 
of exacerbations per year compared with the year before 
entering the study. Something that was not seen in the 
groups receiving salmeterol alone or placebo. However, 
this reduction from 3.5 to 1.2 exacerbations/year cannot be 
compared with any of the other studies since all exacerba-
tions, from mild to severe, were taken into account (Table 2). 
No additional analyses was done for moderate and severe 
exacerbations alone.
Combination therapy with budesonide/
formoterol
Szafranski and colleagues (2003) performed a 12-month 
study in patients with COPD (Table 3), which demonstrated a International Journal of COPD 2007:2(2)  111
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signiﬁ  cantly greater improvement in FEV1 with budesonide/
formoterol (160/4.5 μg bid) versus budesonide (200 μg bid) 
(9%) and placebo (15%), but not versus formoterol 4.5 μg 
bid (1%). Budesonide/formoterol signiﬁ  cantly prolonged 
time to ﬁ  rst exacerbation compared with all other treat-
ments. However, the rate of severe exacerbations was only 
signiﬁ  cantly lower in the combination treatment group (1.42 
exacerbations/patient/year) compared with formoterol (1.84) 
or placebo (1.87), but not compared to budesonide (1.59). 
Interestingly, combination treatment did reduce the rate of 
mild exacerbations (deﬁ  ned as a day with 4 inhalations 
of reliever medication above the mean run-in use) by 35% 
versus budesonide and by 15% versus formoterol, suggesting 
a difference either in the mechanisms underlying mild and 
severe exacerbations or a problem with the deﬁ  nitions of 
exacerbation types. The differences found between severe 
and mild exacerbations might also explain the large differ-
ences in total exacerbations found in the Dal Negro study.
The Szafranski study also revealed that treatment 
with the budesonide/formoterol combination was as-
sociated with a signiﬁ  cantly lower total symptom score 
compared with placebo and budesonide monotherapy and 
Table 2 Inclusion criteria and deﬁ  nitions of studies using ﬂ  uticasone propionate and salmeterol
  Treatment  Inclusion criteria  Exacerbation deﬁ  nition
Mahler et al 2002  Salmeterol/ﬂ  uticasone  FEV1/FVC 70%  Exacerbation was deﬁ  ned by treatment 
  versus ﬂ  uticasone  FEV1 <65% predicted  and resulted in withdrawal from the study
 propionate,  normal  and  >0.70L 
  salmeterol or placebo
Hanania et al 2003  Salmeterol/ﬂ  uticasone  FEV1/FVC 70%  Moderate exacerbation: requiring treatment with .
 versus  ﬂ  uticasone   FEV1 <65% predicted  antibiotics and/
 propionate,  normal  and  >0.70L  or  corticosteroids
  salmeterol or placebo 
      Severe exacerbation: requiring hospitalization
      Discontinuation after 1 exacerbation with inhaled
      or oral corticosteroids or hospitalization or 3
      exacerbations treated with antibiotics 
TRISTAN Calverley  Salmeterol/ﬂ  uticasone   FEV1/FVC ≤70%  Exacerbation: a worsening of COPD symptoms 
et al 2003a  versus ﬂ  uticasone   FEV1 25%–70%  that required treatment with antibiotics, oral 
  propionate,   predicted normal  corticosteroids or both. Episodes that required 
  salmeterol or placebo    corticosteroids treatment of hospital admission
    Reversibility after 400   were noted separately. 
   μg salbutamol: <10% of 
   predicted  normal.   
    At least one exacerbation 
    per year in the last three years.
    At least one exacerbation  
    in the year immediately before 
    the trial entry requiring 
    treatment with oral  
   corticosteroids,  antibiotics 
   or  both.
Dal Negro et al 2003  Salmeterol/ﬂ  uticasone  FEV1/FVC ≤70%  Mild exacerbation: condition requiring
  versus salmeterol FEV1  ≤80% predicted  salbutamol prn >2 occasions/24 h period on 2 or 
 or placebo  normal and >0,80L  more consecutive days compared with the 
      baseline mean of last 7 days of run-in;
    Reversibility after 400 μg  Moderate exacerbations: condition requiring
   salbutamol:  ≤12% as a   treatment with antibiotics and/or
    percent of predicted normal  oral corticosteroids;
    Regular treatment with   Severe exacerbations: condition requiring
    200 mg theophylline bid  emergency hospital treatment
     and/or  hospitalization.
Abbreviations: COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in one second; FVC, forced vital capacityInternational Journal of COPD 2007:2(2)  112
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signiﬁ  cantly reduced reliever medication use (by 1.3 and 0.7 
inhalations/24 h, respectively). 
Calverley and colleagues (2003b) studied the ability of 
different inhalation therapies to maintain the improvement in 
lung function seen after treatment with oral corticosteroids 
and bronchodilators in patients with COPD. Besides a sig-
niﬁ  cant reduction in the exacerbation rate with budesonide/
formoterol (320/9 μg bid) compared with placebo and 
formoterol (9 μg bid), the time to the ﬁ  rst exacerbation was 
signiﬁ  cantly prolonged not only with placebo and formoterol 
but also with budesonide (254, 178, 154, and 96 days for 
budesonide/formoterol, budesonide, formoterol, and placebo 
respectively).
Thus, while some of the results suggest that the mean 
overall change for the combination inhalers is greater than 
the sum of the mean changes for the individual components 
(Mahler et al 2002), the results from these trials have not 
addressed the question of synergistic effects. The TRISTAN 
data do however suggest a possible synergistic effect would 
be more pronounced in COPD patients with more severe 
disease. Further research comparing combination therapy 
delivered via single versus two separate inhaler devices could 
elucidate this issue more clearly (Nannini et al 2004).
A conclusive efﬁ  cacy comparison between the two com-
bination inhalers is difﬁ  cult based on the studies available, 
since no head to head study has been performed to date. 
What can be said is that both combinations led to a signiﬁ  -
cant reduction in exacerbation rate when compared against 
placebo; but in comparison with ICS monotherapy, both 
combinations were unable to show a signiﬁ  cant reduction 
in exacerbation rate. When compared with their constituent 
LABA, a signiﬁ  cant reduction in the exacerbation rate was 
seen for budesonide/formoterol (Szafranski et al 2003) but 
not for salmeterol/ﬂ  uticasone (Calverley et al 2003a; Nannini 
et al 2004). This difference could be the result of a disparities 
in baseline FEV1, since the patients in the Szafranski study 
had a lower mean FEV1 compared with the TRISTAN 
study (36%–37% predicted versus 44.2%–45.0% predicted, 
respectively). Indeed, in the TRISTAN study, the decrease 
in exacerbation rate was more pronounced in patients with 
severe disease. Patients with a baseline FEV1 <50% showed 
a 30% reduction in exacerbations with the combination treat-
ment compared with placebo whereas patients with a baseline 
FEV1 >50% showed only a 10% reduction. 
To complicate matters, in a recent article Suissa (2006) 
criticized, among others, the TRISTAN study for not taking 
into account the between-subject variation when calculating 
the exacerbation rate, thus producing artiﬁ  cial statistical 
signiﬁ  cance.
Individual level
In almost all chronic diseases that are being treated pharma-
cologically, medication adherence and patient compliance 
form a major problem (Haynes et al 2005). Although no 
solid data are available about the compliance of patients with 
COPD in general practice with the use of inhaler medication, 
compliance rates of 71% reported in clinical trial settings are 
not very encouraging (van Grunsven et al 2000). 
Interviews of patients with asthma showed that many 
failed to take their preventive medication regularly (Haugh-
ney et al 2004). Moreover, the majority of respondents 
used their reliever medication most frequently because they 
want to perceive relief from their symptoms immediately. 
The issue of not taking preventive medication regularly 
Table 3 Inclusion criteria and deﬁ  nitions of studies using budesonide and formoterol
  Treatment  Inclusion criteria  Exacerbation deﬁ  nition
Szafranski et al 2003  Budesonide/formoterol  FEV1/FVC 70%  Severe exacerbation: use of oral
 versus budesonide,  FEV1 50% predicted  steroids and/or antibiotics and/or
  formoterol or placebo  normal  hospitalization due to respiratory
   1 severe COPD   symptoms.
    exacerbation within 2–12 
   month  of  ﬁ  rst study visit.
Calverley et al 2003b  Budesonide/formoterol FEV1/FVC 70%  Exacerbations were deﬁ  ned by the
  versus budesonide,  FEV1 50% predicted  required medical intervention: oral 
  formoterol or placebo  normal  antibiotics and/or corticosteroids 
     or  hospitalization.
   1 COPD exacerbation
    requiring antibiotics and/or
    oral corticosteroids within 
    2–12 month of ﬁ  rst study visit.
Abbreviations: COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in one second; FVC, forced vital capacity.International Journal of COPD 2007:2(2)  113
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might be an even larger problem in patients with COPD, 
since the long-term effects of ICS are less obvious in this 
disease. For example, ICS are less effective at preventing 
an exacerbation in COPD (a reduction of 15%–20% versus 
placebo) than in asthma (a reduction of almost 50% in se-
vere asthma) (Calverley 2004). Patients with asthma were 
also reported to be very resistant to a treatment regimen that 
is more complicated than their current two inhaler system 
(“reliever” and “preventer” medication), ideally preferring a 
single inhaler treatment (Haughney et al 2004). A retrospec-
tive, observational, 24-month database study (Stoloff et al 
2004) of medication reﬁ  lls in patients with asthma showed 
that those receiving salmeterol/ﬂ  uticasone combination treat-
ment obtained signiﬁ  cantly more reﬁ  lls compared with the 
number of ﬂ  uticasone reﬁ  lls alone. It was thus concluded 
that salmeterol/ﬂ  uticasone in one inhaler might increase ICS 
reﬁ  ll persistence compared with either ﬂ  uticasone alone in a 
single inhaler or ﬂ  uticasone in combination with salmeterol 
from two separate inhalers. 
The preference for single inhaler treatment combined with 
the desire for rapid symptom relief is likely to be the same for 
patients with COPD. This would make combination inhalers 
containing ICS and LABAs the ﬁ  rst choice of treatment when 
both need to be prescribed to patients with COPD. 
Differences between combinations
As mentioned above, the two combination inhalers are 
difficult to compare since no long-term head to head 
comparisons have been performed in COPD. In patients 
with moderate to severe COPD, comparison of the bron-
chodilator effect of salmeterol/ﬂ  uticasone (50/250 μg) and 
budesonide/formoterol (12/400 μg) showed that both inhaled 
combinations are effective at improving airﬂ  ow limitation 
after acute administration (Cazzola et al 2003). This study 
did show a trend for a faster onset of action for budesonide/
formoterol, but the differences between the two inhalers were 
only signiﬁ  cant after 120 min. The clinical meaning of this 
faster onset of action, however, is questionable for patients 
with COPD who are in need of sustained bronchodilation.
When it comes to inhalation treatment delivery systems, 
metered-dose inhalers (MDIs) and jet nebulizers are equally 
effective in elderly patients, although most patients con-
sider the MDI to be more acceptable and the jet nebulizer 
to be more effective (Balzano et al 2000). Comparing the 
Diskus® (Advair, GlaxoSmithKline, Pittsburgh, PA) with 
the Turbuhaler® (AstraZeneca, Wilmington, DE) dry-powder 
inhalers (DPIs), patients make signiﬁ  cantly fewer errors in 
essential inhalation maneuvers when using a Diskus/Ac-
cuhaler. However, the clinical relevance of these ﬁ  ndings 
is uncertain, since no lung function tests were performed to 
assess the effectiveness of the inhaled medication (van der 
Palen et al 1998).
Research performed by the manufacturer of the Diskus 
(GlaxoSmithKline) showed that in patients with COPD and a 
FEV1 30% predicted, the inspiratory ﬂ  ow was signiﬁ  cantly 
higher through the Diskus than the Turbuhaler (Burnell et al 
2001). Moreover, the Diskus was shown to deliver a more 
consistent dose irrespective of ﬂ  ow than the Turbuhaler in 
this population. However, again, no assessment of effective-
ness was made in this context. 
Given the few head to head comparisons of the two 
combination treatments, no real advantage can be deducted 
for either inhaler from a patient’s perspective.
Safety and tolerability 
of combination treatment in COPD
Given the large proportion of patients with COPD who 
have co-morbidities, safety is a cardinal issue in COPD 
treatment.
The Mahler study (Mahler et al 2002) found no signiﬁ  cant 
differences with respect to cardiac problems when comparing 
Holter monitor results between the treatment groups. Neither 
the Szafranski study (Szafranski et al 2003), the Mahler study 
(Mahler et al 2002), nor the TRISTAN study group (Calverley 
et al 2003a) found any clinically signiﬁ  cant changes in elec-
trocardiograms that could be attributed to treatment.
Pooled analysis in a Cochrane review (Nannini et al 2004) 
of the Mahler, TRISTAN, and Hanania studies showed that 
oropharyngeal candidiasis occurred more frequently in the 
ﬂ  uticasone/salmeterol treatment group than in the groups 
given placebo or salmeterol monotherapy. However, there 
was no signiﬁ  cant difference in the odds of oropharyngeal 
candidiasis affecting those treated with ﬂ  uticasone/salmeterol 
compared with ﬂ  uticasone. 
The TRISTAN study did show a signiﬁ  cant difference 
in serum cortisol concentrations between ﬂ  uticasone and 
placebo at Week 24 and Week 52, and between ﬂ  uticasone/
salmeterol and placebo at Week 24. None of the changes 
were associated with any clinical effects or signs of hypo-
adrenalism. The Mahler study (Mahler et al 2002) reported 
no differences in prestimulated morning plasma cortisol 
concentrations between the treatment groups or differences 
in inappropriate cortisol response to stimulation. 
Overall, the combination treatments would thus appear 
to be as well tolerated as treatment with the individual 
components.International Journal of COPD 2007:2(2)  114
Mensing and Aalbers 
Flexible dosing
Currently, combination inhalers are prescribed as main-
tenance treatment in COPD using ﬁ  xed dosing (Celli and 
MacNee 2004; GOLD 2006). In asthma, however, research 
has examined the possibilities of using combination inhal-
ers more ﬂ  exibly. Since no such studies have yet been 
performed in COPD, it is hard to predict the possibilities of 
such approaches in this indication. Although it is tempting 
to assume that study results would show a similar clinical 
beneﬁ  t in COPD as they do in asthma, one has to keep in mind 
that the diseases differ from each other in many respects.
Two different regimens of ﬂ  exible dosing with ICS/
LABA have been studied in asthma: combination therapy 
as both maintenance and reliever medication (O’Byrne et al 
2005) and adjustable maintenance dosing (AMD) (Aalbers 
et al 2004). Using a combination inhaler for maintenance as 
well as reliever medication might be a possibility in patients 
with COPD who are used to taking short-acting bronchodila-
tors when needed. Research examining the effects of using 
formoterol as maintenance treatment and reliever medication 
(Campbell et al 2005) showed that this concept does work in 
patients with COPD, resulting in a signiﬁ  cant improvement 
in FEV1 compared with formoterol bid and terbutaline as 
needed. Unfortunately no improvements were seen in other 
parameters, such as symptom scores, reliever use, or health-
related quality of life, which are so important for patients with 
COPD. It has to be said that this ﬂ  exible approach has only 
been investigated in asthma for the budesonide/formoterol 
combination, since this combination gives signiﬁ  cantly faster 
bronchodilation than salmeterol/ﬂ  uticasone in acute severe 
asthma (van der Woude et al 2004). As mentioned above, 
this difference seems to be less pronounced in patients with 
COPD (Cazzola et al 2003).
The alternative AMD approach allows patients to in-
crease their maintenance dosing during a limited period of 
time whenever they experience an increase in symptoms. 
Although changes in PEF and FEV1 are usually small 
to begin with, exacerbations in COPD are accompanied 
by a clear deterioration of symptoms (Seemungal et al 
2000; Wedzicha and Donaldson 2003). Hence, adjust-
ment of maintenance dosing based on symptoms and, 
perhaps, reliever medication use might be possible in 
patients with COPD who have a clear perception of their 
disease. Studies using patient diary cards (Seemungal 
et al 1998) show that about half of exacerbations (defined 
as worsening of the COPD symptoms) are not reported 
by the patient to their investigator, even when they are 
urged to do so. This suggests that by leaving the patient 
in charge of adjusting their maintenance medication 
based on symptoms, at least some treatment of unreported 
worsenings of the disease will take place. If an interven-
tion such as the AMD approach will lead to a decrease 
in the level of severe exacerbation remains to be seen. 
This approach is partly based on self-management of 
the disease, a concept that has been proven successful in 
asthma (Toelle and Ram 2004) but is still under debate 
in COPD (Monninkhof et al 2003). Nevertheless, recent 
studies show that self-management in COPD can lead to 
a reduction of hospital admissions due to an exacerbation 
(Bourbeau et al 2003) and may decrease the number of 
exacerbations experienced (Hutchinson et al 2006). 
There is currently little evidence to predict if ﬂ  exible 
treatment with LABA/ICS combination inhalers will improve 
disease control in COPD. However, based on results in 
patients with asthma, this treatment option seems worth 
investigating in COPD. 
Conclusion
There is some evidence to suggest that using a combination 
inhaler is preferable to using the individual components 
separately in COPD when both components are prescribed. 
A vast number of studies demonstrated an improvement in 
symptom scores, PEF, FEV1, reliever medication use, and, 
possibly, exacerbation rates when the use of combination 
inhalers is compared with that of the individual components 
in COPD. However, it remains unclear if there is anything to 
be gained from using combination inhalers in patients with 
less severe COPD. The clinical studies presented here mostly 
used FEV1 <65% or FEV1 50% of predicted normal as an 
inclusion criterion. The TRISTAN study was the only large 
study to also include COPD patients with less severe COPD. 
They demonstrated a greater reduction in the exacerbation 
rate for the group with an FEV1 <50% predicted compared 
with the patients with an FEV1 >50% predicted. It will be 
interesting to see if other studies, including more mild cases 
of COPD, will come to the same conclusion.
As for the differences between the two available combi-
nations (budesonide/formoterol and salmeterol/ﬂ  uticasone), 
there is no evidence to suggest an advantage for one product 
over the other. The usage of the inhalers themselves is some-
what different, possibly leading to different mistakes being 
made by patients while using them. It is therefore important 
for the treating physician to be attentive towards any mistakes 
in patients’ inhalation technique. If patients frequently make 
the same errors, the physician should consider changing the 
patient’s device. International Journal of COPD 2007:2(2)  115
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The option to recommend the use of a combination in-
haler in a self-management plan in patients with COPD is a 
possibility well worth exploring in the future.
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